化学
药效学
溶解
药理学
药物发现
组分(热力学)
药品
生物化学
组合化学
生物利用度
作者
Kalyani Sakure,Alok Singh Thakur,Madhulika Pradhan,Hemant Badwaik
标识
DOI:10.1080/22297928.2026.2676151
摘要
Brinzolamide (BRZ) is a selective carbonic anhydrase inhibitor recommended for the topical treatment of primary open-angle glaucoma. Despite its promising therapeutic characteristics, BRZ has significant limitations of low water solubility and poor dissolution. To address these challenges, we developed a BRZ co-crystals with p-aminobenzoic acid (PABA). A synthesized BRZ-PABA binary system was characterized by FTIR, Powder XRD, SEM and thermogravimetric analysis. Spectroscopic characterization suggests the presence of intermolecular interactions indicative of a potential new solid phase BRZ-PABA cocrystal. Saturation solubility results revelled that F7 showed a 115.35% and 208.45% improvement in solubility in water and STF, respectively. Similarly, the improvement in dissolution (80.30 % improvement in T50) is shown. The ex vivo permeability showed enhanced permeation rate of BRZ through F7 (411.3 ± 12.72 μg/h) compared to the marketed formulation (364.12 ± 9.26 μg/h) and free drug (313.89 ± 6.35 μg/h). Also, the co-crystals of BRZ showed a good ocular tolerability and comparatively stronger IOP-reducing effect and a faster recovery toward normal values. Thus, the reported co-crystals have significant implications for employing a co-crystallization strategy to enhance BRZ permeability and efficacy in the pharmaceutical domain. Additionally, findings underscored the growing significance of pharmaceutical co-crystals in drug development.
科研通智能强力驱动
Strongly Powered by AbleSci AI